Monopar Therapeutics Files Proxy Materials

Ticker: MNPR · Form: DEFA14A · Filed: 2025-05-23T00:00:00.000Z

Sentiment: neutral

Topics: proxy-filing, regulatory, sec-filing

Related Tickers: MNPR

TL;DR

Monopar files proxy docs, no fee. Standard stuff.

AI Summary

Monopar Therapeutics Inc. filed a Definitive Additional Materials proxy statement on May 23, 2025. This filing relates to the company's proxy materials and does not involve a fee. The company is incorporated in Delaware and its fiscal year ends on December 31.

Why It Matters

This filing is a routine regulatory submission for Monopar Therapeutics, providing shareholders with information related to upcoming corporate decisions or meetings.

Risk Assessment

Risk Level: low — This is a routine administrative filing with the SEC and does not contain new financial information or strategic decisions that would immediately impact the stock price.

Key Players & Entities

FAQ

What type of filing is this?

This is a Definitive Additional Materials filing (DEFA14A) for Monopar Therapeutics Inc.

When was this filing submitted?

The filing was submitted on May 23, 2025.

Is there a fee associated with this filing?

No fee is required for this filing.

What is the company's fiscal year end?

Monopar Therapeutics Inc.'s fiscal year ends on December 31.

Where is Monopar Therapeutics Inc. incorporated?

Monopar Therapeutics Inc. is incorporated in Delaware (DE).

From the Filing

0001437749-25-018329.txt : 20250523 0001437749-25-018329.hdr.sgml : 20250523 20250523154833 ACCESSION NUMBER: 0001437749-25-018329 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20250523 DATE AS OF CHANGE: 20250523 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 25981844 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 DEFA14A 1 mnpr20250523_defa14a.htm FORM DEFA14A mnpr20250523_defa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934(Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material under §240.14a-12 MONOPAR THERAPEUTICS INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒ No fee required. ☐ Fee paid previously with preliminary materials. ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a–6(i)(1) and 0–11. GRAPHIC 2 prxy01.jpg begin 644 prxy01.jpg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

View on Read The Filing